西妥昔单抗通过EGFR-GEP100-Arf6-AMAP1通路抑制头颈癌上皮-间质转化
在4株头颈鳞癌细胞系及异种移植模型中,西妥昔单抗通过抑制EGFR-GEP100-Arf6-AMAP1通路,抑制迁移、侵袭、上皮-间质转化及淋巴结转移,但不抑制癌细胞增殖;其生存获益可能归因于抗上皮-间质转化作用。
要点
- 西妥昔单抗抑制头颈鳞癌细胞迁移、侵袭和上皮-间质转化。
- 西妥昔单抗通过抑制EGFR-GEP100-Arf6-AMAP1通路发挥作用。
- 西妥昔单抗不抑制头颈鳞癌细胞增殖。
核心结论
- 西妥昔单抗联合化疗或放疗带来的生存改善,可能归因于其通过抑制EGFR-GEP100-Arf6-AMAP1通路而产生的抗上皮-间质转化作用。
研究设计与样本
- 研究在4株头颈鳞癌细胞系中检测西妥昔单抗对增殖、迁移、侵袭、上皮-间质转化及EGFR下游信号事件的影响,并在异种移植模型中评估其体内疗效。
主要发现
- 西妥昔单抗通过抑制EGFR-GEP100-Arf6-AMAP1通路,抑制迁移、侵袭、上皮-间质转化和淋巴结转移,但不抑制癌细胞增殖。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite improved survival by the addition of a monoclonal antibody against epidermal growth factor receptor (EGFR), cetuximab, to chemotherapy or radiotherapy for squamous cell carcinoma of the head and neck (SCCHN), cetuximab by itself is not a potent antiproliferative agent against SCCHN. We aimed to elucidate working mechanism of cetuximab in SCCHN. METHODS: The effect of cetuximab on the proliferation, migration, invasion, epithelial-mesenchymal transition, and signaling events downstream of the EGFR were investigated in 4 SCCHN cell lines. The in vivo efficacy of cetuximab was evaluated in a xenotransplant model. RESULTS: Cetuximab inhibited migration, invasion, epithelial-mesenchymal transition, and lymph node metastasis by suppressing EGFR-GEP100-Arf6-AMAP1 pathway, but it did not inhibit cancer cell proliferation. CONCLUSION: The improved survival by the addition of cetuximab is likely to be attributable to the antiepithelial-mesenchymal transition action of cetuximab via inhibiting EGFR-GEP100-Arf6-AMAP1 pathway. © 2016 Wiley Periodicals, Inc. Head Neck 39: 476-485, 2017.
引用
- Matsumoto Y, Sakurai H, Kogashiwa Y, et al. Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer. Head Neck. 2016. PMID: 27880014. doi:10.1002/hed.24626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。